SNMMI Procedure Standard/EANM Practice Guideline for Amyloid PET Imaging of the Brain 1.0

1University of Utah, Salt Lake City, Utah; 2University of Cologne, Cologne, Germany; 3University Hospital Leipzig, Leipzig, Germany; 4VA Medical Center, University of Michigan, Ann Arbor, Michigan; 5Yale University, New Haven, Connecticut; 6Harborview Medical Center, Seattle, Washington; 7University of Pittsburgh, Pittsburgh, Pennsylvania; 8Mallinckrodt, St. Louis, Missouri; 9Karolinska Institutet, Stockholm, Sweden; 10University Hospital Leipzig, Leipzig, Germany; 11Institute for Neurodegenerative Disorders, New Haven, Connecticut; 12Beth Israel Deaconess Medical Center, Boston, Massachusetts; and 13University Hospital Leuven, Leuven, Belgium

[1]  Keith A. Johnson,et al.  Update on Appropriate Use Criteria for Amyloid PET Imaging: Dementia Experts, Mild Cognitive Impairment, and Education , 2013, The Journal of Nuclear Medicine.

[2]  C. Rowe,et al.  Radiation Dosimetry of β-Amyloid Tracers 11C-PiB and 18F-BAY94-9172 , 2009, Journal of Nuclear Medicine.

[3]  J. Schneider,et al.  National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease , 2012, Alzheimer's & Dementia.

[4]  W. Klunk.  Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia , 2011, Neurobiology of Aging.

[5]  T. Yen,et al.  Whole-body biodistribution and brain PET imaging with [18F]AV-45, a novel amyloid imaging agent--a pilot study. , 2010, Nuclear medicine and biology.

[6]  Keith A. Johnson,et al.  Update on appropriate use criteria for amyloid PET imaging: Dementia experts, mild cognitive impairment, and education , 2013, Alzheimer's & Dementia.

[7]  Nick C Fox,et al.  Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria , 2014, The Lancet Neurology.

[8]  P. Scheltens,et al.  Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria , 2007, The Lancet Neurology.

[9]  T. Yen,et al.  Correlation of early-phase 18F-florbetapir (AV-45/Amyvid) PET images to FDG images: preliminary studies , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[10]  R. Vandenberghe,et al.  Whole-Body Biodistribution and Radiation Dosimetry of 18F-GE067: A Radioligand for In Vivo Brain Amyloid Imaging , 2009, Journal of Nuclear Medicine.

[11]  Keith A. Johnson,et al.  Appropriate Use Criteria for Amyloid PET: A Report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association , 2013, The Journal of Nuclear Medicine.

[12]  Masanori Nakagawa,et al.  High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types. , 2009, Archives of neurology.

[13]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[14]  Urso FORTE. Urso.  HIGHLIGHTS OF PRESCRIBING INFORMATION , 2007 .

[15]  Victor L. Villemagne,et al.  Brain Amyloid Imaging , 2011, The Journal of Nuclear Medicine.

[16]  Charles Duyckaerts,et al.  National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach , 2011, Acta Neuropathologica.